Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437415 | 0.86 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL16054218 | 0.85 | RPS6KA5 (0.41) | RPS6KA5 | |
| SCHEMBL17437551 | 0.82 | POLB (0.36) | RPS6KA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17437430 | 0.81 | POLB (0.40) | RPS6KA5POLBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16053930 | 0.78 | RPS6KA5 (0.48) | RPS6KA5 | |
| SCHEMBL16054588 | 0.70 | RPS6KA5 (0.37) | RPS6KA5 | |
| SCHEMBL16054180 | 0.70 | RPS6KA5 (0.41) | RPS6KA5POLB | |
| SCHEMBL17437338 | 0.69 | PI4K2A (0.41) | POLB | |
| SCHEMBL17437546 | 0.67 | RPS6KA5 (0.35) | RPS6KA5 | |
| SCHEMBL16054184 | 0.67 | ROCK1 (0.33) | RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9512120-B2 | Microbicidally active imidazopyridine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | RPS6KA5 2731/4885POLB 1804/4885CYP1A2 25/4885 |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | RPS6KA5 2731/4885POLB 1804/4885CYP1A2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.